Predictive Value of TLR7 Polymorphism for Cetuximab-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

International Journal of Cancer - United States
doi 10.1002/ijc.30810
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

The Predictive Value of 18f-FDG-Pet Early Evaluation in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy Plus Cetuximab

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2007English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study

Oncotarget
Oncology
2016English

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Rechallenge and Maintenance Therapy Using Cetuximab and Chemotherapy Administered to a Patient With Metastatic Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer
Cancer ResearchOncology
2017English

Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2011English

Cetuximab Retreatment in Patients With Metastatic Colorectal Cancer Who Exhibited a Clinical Benefit in Response to Prior Cetuximab: A Retrospective Study

Oncology Letters
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy